Pfizer's stock is experiencing an uptick today, likely influenced by a combination of factors. Notably, State Street Corp has increased its stake in Pfizer by 1.2% during the third quarter, as disclosed in their recent SEC filing. This move, along with other institutional investors modifying their holdings, suggests a growing confidence in Pfizer's potential. Additionally, Pfizer's strategic pivot towards the oncology market and its upgraded 2024 guidance have been highlighted as positive developments, indicating a potential upside for the stock.
Pfizer's shares are currently trading at $25.75, reflecting a 2.08% increase from the previous close of $25.23.